Abstract 17147: No Changes in Average Lipid Profiles in the United States From 2003 to 2012: The National Health and Nutrition Examination Survey 2003-2012
Introduction: Lipid-lowering therapies (LLT) are now regularly used in the management of dyslipidemia, but it is not known how the increased use of LLT has influenced lipid levels of the US population. We determined the average lipid profiles of the US population from 2003-2012 in the National Health and Nutrition Examination Survey (NHANES).
Methods: Coronary heart disease risk using NCEP ATP III criteria was assessed in adult participants in 2-yearly NHANES surveys from 2003-2004 to 2011-2012. Fasting serum values were used to determine lipid profiles of men and women in each risk group. The proportion of participants in each risk group receiving LLT was also calculated.
Results: Estimates for the US population were based on 11,256 observations in NHANES from 2003-2012. From the 2003-2004 survey to the 2011-2012 survey, a significant increase in the use of LLT was observed in the low- (6% to 11%; p<0.0001) and high-risk (41% to 52%; p=0.008) groups. A possible trend for reduction in median triglyceride (TG) levels was observed in women in the high-risk group only, from 170 mg/dL (2003-2004) to 127 mg/dL (2011-2012). However, sample sizes are small (165-248 participants), and variability is high; therefore, this may impact on the applicability of the TG results. For both men and women and in all risk categories, no obvious trend for change in mean levels of non-high-density lipoprotein cholesterol (non-HDL-C), low-density lipoprotein cholesterol (LDL-C), and HDL-C was observed (Figure). Mean HDL-C levels were higher in women than in men in all risk groups, consistently over the time period (Figure).
Conclusion: Despite an increase in the use of LLT, we observed no trend for change in lipid profiles in low-, intermediate- or high-risk men and women in the US population. This may be due to the variability in response to LLT, and highlights the need for more aggressive identification and treatment of high-risk individuals, as recommended in the ACC/AHA guideline.
Author Disclosures: P.P. Toth: Speakers Bureau; Modest; Genzyme. Speakers Bureau; Significant; Amarin, AstraZeneca, GSK, Kowa, and Merck and Co.. Consultant/Advisory Board; Modest; Amgen, AstraZeneca, Merck and Co, Novartis, Sanofi-Regeneron. M.K. Palmer: Other; Modest; AstraZeneca. K.M. Henriksson: Employment; Significant; AstraZeneca.
- © 2015 by American Heart Association, Inc.